Immutep PRRUF Stock
Immutep Price Chart
Immutep PRRUF Financial and Trading Overview
| Immutep stock price | 0.04 USD |
| Previous Close | 0.04 USD |
| Open | 0.03 USD |
| Bid | 0.03 USD x 3000000 |
| Ask | 0.05 USD x 3000000 |
| Day's Range | 0.03 - 0.04 USD |
| 52 Week Range | 0.03 - 0.33 USD |
| Volume | 30K USD |
| Avg. Volume | 480 USD |
| Market Cap | 55.85M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PRRUF Valuation Measures
| Enterprise Value | -12042597 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.4348786 |
| Price/Book (mrq) | 0.8006676 |
| Enterprise Value/Revenue | -0.525 |
| Enterprise Value/EBITDA | 0.158 |
Trading Information
Immutep Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -78.94% |
| S&P500 52-Week Change | 20.20% |
| 52 Week High | 0.33 USD |
| 52 Week Low | 0.03 USD |
| 50-Day Moving Average | 0.05 USD |
| 200-Day Moving Average | 0.13 USD |
PRRUF Share Statistics
| Avg. Volume (3 month) | 480 USD |
| Avg. Daily Volume (10-Days) | 3.03K USD |
| Shares Outstanding | 1.47B |
| Float | 1.43B |
| Short Ratio | N/A |
| % Held by Insiders | 3.02% |
| % Held by Institutions | 48.44% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -192.52% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.88% |
| Return on Equity (ttm) | -77.30% |
Income Statement
| Revenue (ttm) | 22.94M USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | 135.40% |
| Gross Profit (ttm) | 22.94M USD |
| EBITDA | -76113960 USD |
| Net Income Avi to Common (ttm) | -79304560 USD |
| Diluted EPS (ttm) | -0.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 68.87M USD |
| Total Cash Per Share (mrq) | 0.05 USD |
| Total Debt (mrq) | 1.05M USD |
| Total Debt/Equity (mrq) | 1.7 USD |
| Current Ratio (mrq) | 5.694 |
| Book Value Per Share (mrq) | 0.0473355 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -55463740 USD |
| Levered Free Cash Flow (ttm) | -36705980 USD |
Profile of Immutep
| Country | United States |
| State | NSW |
| City | Sydney |
| Address | Australia Square |
| ZIP | 2000 |
| Phone | 61 2 8315 7003 |
| Website | https://www.immutep.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Q&A For Immutep Stock
What is a current PRRUF stock price?
Immutep PRRUF stock price today per share is 0.04 USD.
How to purchase Immutep stock?
You can buy PRRUF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immutep?
The stock symbol or ticker of Immutep is PRRUF.
Which industry does the Immutep company belong to?
The Immutep industry is Biotechnology.
How many shares does Immutep have in circulation?
The max supply of Immutep shares is 1.47B.
What is Immutep Price to Earnings Ratio (PE Ratio)?
Immutep PE Ratio is now.
What was Immutep earnings per share over the trailing 12 months (TTM)?
Immutep EPS is -0.04 USD over the trailing 12 months.
Which sector does the Immutep company belong to?
The Immutep sector is Healthcare.
